The biopharmaceutical company, SELLAS Life Sciences, has presented results from its Phase II galinpepimut-S trial at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting.

Galinpepimut-S is a peptide vaccine that targets WT1, a protein expressed on the surface of myeloma cells, and stimulates a CD4+ and CD8+ immune response. The trial looked at the efficacy of the vaccine in myeloma patients with high risk cytogenetics who had achieved a positive minimal residual disease (MRD) status following an autologous stem cell transplant (ASCT). The results show that median progression-free survival for patients receiving galinpepimut-s was 23.6 months.

Read article